Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XM Isocitrate dehydrogenase (IDH) inhibitors
L01XM03 Olutasidenib
D12483 Olutasidenib (USAN/INN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
IDH1 Enzyme Inhibitors
Olutasidenib
D12483 Olutasidenib (USAN/INN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D12483 Olutasidenib
Unclassified
DG03328 Isocitrate dehydrogenase inhibitor
D12483 Olutasidenib
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Dehydrogenases
IDH1* [HSA_VAR:3417v1]
D12483 Olutasidenib (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D12483
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D12483
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D12483
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D12483